Comparative Pharmacology
Head-to-head clinical analysis: ALYFTREK versus DEXONE 0 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYFTREK versus DEXONE 0 5.
ALYFTREK vs DEXONE 0.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALYFTREK (vutrisiran) is a transthyretin-directed small interfering RNA that binds to the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference, thereby reducing hepatic production of TTR protein and decreasing amyloid deposition.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor (GR) and modulating gene expression through transactivation and transrepression. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, suppresses cytokine production (IL-1, IL-2, IL-6, TNF-alpha), and decreases immune cell migration and activation.
For patients with cystic fibrosis (CF) who are heterozygous for the F508del mutation in the CFTR gene and a minimal function mutation (F/MF genotypes): elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 125 mg orally, two tablets in the morning, and ivacaftor 150 mg orally, one tablet in the evening, approximately 12 hours apart. For patients homozygous for F508del (F/F genotypes): elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 125 mg orally, two tablets in the morning, and ivacaftor 150 mg orally, one tablet in the evening.
0.5 mg orally once daily, with gradual taper to lowest effective dose
None Documented
None Documented
Terminal elimination half-life is approximately 72 hours after single dose and extends to ~120 hours at steady state due to dose-dependent elimination; allows once-weekly dosing.
3.0-4.5 hours; prolonged in hepatic impairment (up to 6-8 hours) or concurrent CYP3A4 inhibitors
Primarily hepatic metabolism, with ~70% excreted in feces as metabolites and ~20% in urine (mostly as metabolites). <1% excreted unchanged in urine.
Renal: 70-80% (mostly as 6β-hydroxydexamethasone); biliary/fecal: 10-15%
Category C
Category C
Corticosteroid/Beta2-Agonist Combination
Corticosteroid